Medicare Enrolled
Dr. Amirreza Solhpour, M.D.
Cardiovascular Disease · Lufkin, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Solhpour from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Solhpour? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Solhpour
Dr. Amirreza Solhpour is a cardiovascular disease in Lufkin, TX, with 13 years in practice. Based on federal Medicare data, Dr. Solhpour performed 12,873 Medicare services across 6,728 unique beneficiaries.
Between the years covered by Open Payments, Dr. Solhpour received a total of $22,261 from 53 pharmaceutical and/or device companies across 916 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Solhpour is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years in practice▲ Top 2% volume in TX$ $22,261 industry payments
Medicare Practice Summary
Medicare Utilization ↗12,873
Medicare services
Top 2% in TX for cardiovascular disease
6,728
Unique beneficiaries
$76
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~990 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 2,204 | $0 | $5 |
| Hospital follow-up visit, high complexity | 1,599 | $100 | $223 |
| EKG interpretation and report | 1,587 | $7 | $19 |
| Office visit, established patient (30-39 min) | 1,359 | $106 | $300 |
| Infusion, normal saline solution, 250 cc | 816 | $1 | $1 |
| Ultrasound of both sides of head and neck blood flow | 539 | $83 | $427 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 408 | $98 | $130 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 382 | $90 | $411 |
| Electrocardiogram (EKG), 12-lead | 351 | $12 | $38 |
| Echocardiogram, transthoracic | 340 | $171 | $413 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 275 | $312 | $779 |
| Ultrasound of leg arteries or artery grafts | 264 | $121 | $593 |
| Initial hospital admission, high complexity | 229 | $145 | $330 |
| Ultrasound scan of abdominal aorta | 225 | $62 | $271 |
| Critical care, first 30-74 min | 214 | $179 | $369 |
| Regadenoson injection (Lexiscan) for heart stress test | 212 | $48 | $70 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 209 | $55 | $160 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 193 | $66 | $255 |
| Nursing facility visit, moderate complexity | 175 | $91 | $212 |
| Office visit, established patient (20-29 min) | 166 | $75 | $205 |
| Emergency department visit, moderate complexity | 149 | $100 | $276 |
| Smoking and tobacco use intensive counseling, more than 10 minutes | 135 | $29 | $74 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 102 | $10 | $141 |
| New patient office visit (45-59 min) | 98 | $132 | $357 |
| Chemical destruction of first incompetent vein of arm or leg using imaging guidance | 95 | $1,557 | $3,178 |
| Ultrasonic guidance for blood vessel access | 91 | $12 | $60 |
| Ultrasound of heart with probe in esophagus, with report | 87 | $88 | $424 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) | 71 | $24 | $83 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 71 | $11 | $30 |
| Ultrasound of heart, follow-up | 47 | $21 | $222 |
| Cardiac catheterization | 36 | $187 | $1,832 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 29 | $52 | $151 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 26 | $18 | $49 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 25 | $183 | $701 |
| Coronary stent placement | 20 | $446 | $820 |
| Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | 19 | $154 | $366 |
| Complete ultrasound scan of abdomen | 13 | $72 | $319 |
| Review by radiologist of abdominal aorta and both leg arteries image | 12 | $77 | $258 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
9.4% high complexity
38.2% medium
52.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$22,261
Total received (2018-2024)
Avg $3,180/year across 7 years
Top 18% in TX for cardiovascular disease
53
Companies
916
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$22,261 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$3,945
2023$3,809
2022$3,370
2021$2,243
2020$1,362
2019$3,974
2018$3,557
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Abbott Laboratories
$3,555
Novartis Pharmaceuticals Corporation
$2,585
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$1,819
Boston Scientific Corporation
$1,717
Medtronic Vascular, Inc.
$1,482
Amgen Inc.
$1,175
AstraZeneca Pharmaceuticals LP
$1,138
Boehringer Ingelheim Pharmaceuticals, Inc.
$963
Edwards Lifesciences Corporation
$875
E.R. Squibb & Sons, L.L.C.
$720
Esperion Therapeutics, Inc.
$683
Merck Sharp & Dohme LLC
$615
ABIOMED
$520
Kiniksa Pharmaceuticals, Ltd.
$382
PFIZER INC.
$358
Janssen Pharmaceuticals, Inc
$326
Lexicon Pharmaceuticals, Inc.
$298
Kowa Pharmaceuticals America, Inc.
$286
Baylis Medical Company Inc
$274
Novo Nordisk Inc
$272
Medtronic, Inc.
$255
Actelion Pharmaceuticals US, Inc.
$234
iRhythm Technologies, Inc.
$171
Cook Incorporated
$157
CathWorks, Inc.
$145
Impulse Dynamics (USA) Inc.
$142
Kiniksa Pharmaceuticals International, plc
$119
SANOFI-AVENTIS U.S. LLC
$109
Cook Medical LLC
$94
Kestra Medical Technology Services, Inc.
$82
Merck Sharp & Dohme Corporation
$77
Alnylam Pharmaceuticals Inc.
$74
Otsuka America Pharmaceutical, Inc.
$73
HEARTFLOW, INC.
$57
Amarin Pharma Inc.
$47
Philips North America LLC
$38
Siemens Medical Solutions USA, Inc.
$34
GE HealthCare
$25
Cardiovascular Systems Inc.
$24
Chiesi USA, Inc.
$23
Bayer Healthcare Pharmaceuticals Inc.
$23
CVRx, Inc.
$23
AtriCure, Inc.
$22
BIOTRONIK INC.
$21
ATRICURE, INC.
$20
Terumo Medical Corporation
$20
ARBOR PHARMACEUTICALS, INC.
$19
Bayer HealthCare Pharmaceuticals Inc.
$18
W. L. Gore & Associates, Inc.
$17
SCPHARMACEUTICALS INC.
$17
CARDIVA MEDICAL, INC.
$16
Preventice Services, LLC
$14
Shockwave Medical, Inc
$11
Top 3 companies account for 35.8% of total payments
Associated products mentioned in payments ›
(5044) MCOT · 3F · ABSOLUTE PRO · ACCOLADE · AMPLATZER · AMPLATZER AMULET · AMPLATZER Occluders · AMPLATZER PICCOLO · AMVUTTRA · AVALUS · AVEIR · Arcalyst · Artis pheno · Asahi Fielder coronary guide wire · Assure WCD · BG Mini Plus · BIOMONITOR · BRILINTA · Barostim Neo System · BodyGuardian · CAMZYOS · CARDIOMEMS · CARDIVA VASCADE 6/7F VCS · COOK · COOK MEDICAL AAA · COOK MEDICAL STENTS · COREVALVE EVOLUT R · COROFLOW · CardioMEMS HF System · ClosureFast · Cobalt · Confida · Cook Medical AAA · CoreValve Evolut · Corlanor · DIAMONDBACK CORONARY · DIAMONDBACK PERIPHERAL · DRAGONFLY OPSTAR · DYNAGEN · EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) · ELIQUIS · EMBOSHIELD NAV6 · ENTRESTO · EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX · Edarbi · Edwards SAPIEN 3 Transcatheter Heart Valve · Edwards SAPIEN 3 Ultra Transcatheter Heart Valve · FARXIGA · FFRangio System · FFRct · FUROSCIX · GENERAL - STRUCTURAL HEART · GENERAL THERAPIES · GORE EXCLUDER Iliac Branch Endoprosthesis · Glidesheath · HI-TORQUE COMMAND · HI-TORQUE CONNECT · HI-TORQUE PILOT · INNOVA · Impella · Inpefa · JARDIANCE · JETI · JETI ALL IN ONE NON-STERILE KIT · KENGREAL · Kerendia · LEQVIO · LIVALO · LUX-Dx Insertable Cardiac Monitor · LifeVest · Livalo · MICRA · MINI TREK · MITRACLIP · MULTAQ · Micra · Mitra Clip system · MitraClip System · NAVITOR · NC TREK NEO · NEXLETOL · NEXLIZET · NRG · OMNILINK ELITE · OPSUMIT · OPTIMIZER · OPTIS · Optimizer · Ozempic · PASCAL · PERCLOSE PROGLIDE · PERCLOSE PROSTYLE · PRADAXA · PRALUENT · PRESSUREWIRE · Perclose ProGlide suture mediated closure system · Perclose ProStyle · Peripheral Orbital Atherectomy System · Q GUIDE ELECTRODE · RESONATE · RESONATE EL ICD VR · ROSEN · Repatha · Rybelsus · S-ICD System Magnet · SAMSCA · SAPIEN 3 Ultra RESILIA · SQRX PULSE GENERATOR · Sentinel · SpiderFX · UPTRAVI · VENASEAL · VERQUVO · VYNDAQEL · Varithena Administration Pack · Vascepa · Vascular Lithotripsy · VenaSeal · Verquvo · WATCHMAN · WATCHMAN Access System · WATCHMAN FLX · XARELTO · XIENCE SKYPOINT · ZILVER PTX · ZIO XT Patch · Zio monitor
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $173 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
11
Per 100K population
12.7
County median income
$58,847
Nearest hospital
WOODLAND HEIGHTS MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Solhpour is a mixed practice specialist, with above-average Medicare volume (top 2% in TX), and high industry engagement (low-engagement, top 18%).
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Solhpour experienced with injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)?
Based on Medicare claims data, Dr. Solhpour performed 2,204 injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Solhpour receive payments from pharmaceutical companies?
Yes. Dr. Solhpour received a total of $22,261 from 53 companies across 916 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Solhpour's costs compare to other cardiovascular diseases in Lufkin?
Dr. Solhpour's average Medicare payment per service is $76. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Solhpour) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Lufkin
Browse cardiovascular diseases in Lufkin ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in TX
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in TX
Which TX cardiovascular diseases receive the most from drug and device companies.
By company
Abbott Laboratories Payments to Doctors
See all physicians who received payments from Abbott Laboratories.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) Payments to Doctors
See all physicians who received payments from ZOLL Services LLC (A/K/A ZOLL LifeCor Corp).
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology